Clinical trialNCT03815682TerminatedPhase 1Interventional

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

SponsorRepertoire Immune MedicinesEnrollment23LymphomaSolid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David Spriggs, MD
Repertoire Immune Medicines
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Carolina Biooncology Institute
Huntersville, North Carolina, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Arm A: RPTR-147:1Arm B: RPTR-147:1 and PembrolizumabArm C: RPTR-147:2

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Oct 2018
Primary completion: 7 Sept 2022
Completion: 11 Oct 2022
Last update posted: 6 Dec 2022
Registered enrollment: 23
Registry id: NCT03815682

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.